Apparently also overpriced was Celgene, Regeneron, Gilead, Isis and on and on and on. There has been a rotation out of the biotechs. It is no reflection on any particular Company. It is a sector issue. I don't own any JAZZ. The charts may suggest a continued decline. However, I would be a buyer of any on the list at these prices.
News 
Market Data 
Discover 
